Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Developing an HCV Vaccine Faces Significant Challenges

Key clinical point: Significant barriers continue to prevent the development of a prophylactic HCV vaccine.

Major finding: HCV has 7 known genotypes and more than 80 subtypes, a genetic diversity exceeding that of HIV-1.

Study details: A literature review of the HCV vaccine development field.

Disclosures: Dr. Bailey and his colleagues reported that they had no conflicts.


Bailey JR et al. Gastroenterology 2019;156(2):418-30.